Brokerages Set STAAR Surgical (NASDAQ:STAA) Price Target at $42.83

STAAR Surgical (NASDAQ:STAA) has been assigned a consensus rating of “Hold” from the nine brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $42.83.

Several equities analysts recently commented on STAA shares. Canaccord Genuity Group cut their price target on shares of STAAR Surgical from $31.00 to $28.00 and set a “hold” rating on the stock in a report on Monday, December 9th. Stephens raised STAAR Surgical to a “hold” rating in a research report on Monday, December 2nd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research report on Tuesday.

STAAR Surgical Stock Down 3.2 %

Shares of STAAR Surgical stock opened at $23.12 on Monday. The business has a 50-day moving average price of $26.43 and a 200-day moving average price of $32.94. STAAR Surgical has a twelve month low of $22.40 and a twelve month high of $52.68. The firm has a market cap of $1.14 billion, a price-to-earnings ratio of 52.55 and a beta of 0.63.

Insider Activity at STAAR Surgical

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. purchased 23,000 shares of the stock in a transaction dated Wednesday, December 18th. The stock was acquired at an average cost of $24.33 per share, for a total transaction of $559,590.00. Following the acquisition, the insider now owns 10,848,631 shares in the company, valued at $263,947,192.23. This trade represents a 0.21 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in STAA. Arcadia Investment Management Corp MI purchased a new stake in STAAR Surgical during the third quarter worth approximately $37,000. Quarry LP acquired a new stake in STAAR Surgical during the 3rd quarter worth $50,000. Canada Pension Plan Investment Board acquired a new position in STAAR Surgical in the second quarter valued at $129,000. Larson Financial Group LLC acquired a new stake in shares of STAAR Surgical during the second quarter worth about $130,000. Finally, Quest Partners LLC purchased a new stake in shares of STAAR Surgical in the 3rd quarter valued at about $128,000. Institutional investors and hedge funds own 96.70% of the company’s stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.